Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Ozempic Shows Some Promise for Alcohol Use Disorder
The results suggest the potential of semaglutide – the main ingredient in Ozempic and Novo’s higher-dose weight-loss drug ...
The Motley Fool12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two ...
Morningstar9d
Novo Nordisk's Wegovy Drug Sales Miss Expectations
Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations ... The sales performance comes after Eli Lilly, the company's biggest competitor in the booming weight-loss ...
NBC Los Angeles9d
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
It's been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo's obesity drug Wegovy is losing ... 2025 outlook on Wednesday. Get top local stories in Southern ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
U.S. News & World Report9d
Novo Nordisk Defends Next-Gen Obesity Drug CagriSema, Details New Trial
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation ... Lilly emerges as a strong competitor in the biggest market for obesity drugs, the United States. Novo plans to begin ...